home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650214.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
2KB
|
35 lines
Document 0214
DOCN M9650214
TI Treatment with an anti-CD4 monoclonal antibody strongly ameliorates
established rat adjuvant arthritis.
DT 9605
AU Pelegri C; Morante MP; Castellote C; Franch A; Castell M; Unit of
Physiology, Faculty of Pharmacy, University of Barcelona,; Spain.
SO Clin Exp Immunol. 1996 Feb;103(2):273-8. Unique Identifier : AIDSLINE
MED/96152676
AB Some experimental arthritic diseases can be prevented by treatment with
anti-CD4 MoAbs. Trials with ongoing disease have not been successful so
far. The aim of this study was to ascertain whether W3/25 could reverse
adjuvant arthritis (AA), when beginning treatment on day 14, i.e. when
the disease was established. Moreover, one group of animals treated with
the anti-CD4 MoAb received OX8 MoAb at the same time, thus depleting
CD8+ cells from circulation. During treatment with W3/25, a strong
amelioration of inflammatory signals were observed, as assessed by means
of paw volume increase and arthritic score. However, when treatment
stopped, a rebound to arthritis signals occurred. The parallel depletion
of CD8+ cells did not modify these effects, thus the combined treatment
W3/25 + OX8 gave the same amelioration as treatment with W3/25 alone.
These findings indicate that CD4+ cells play an important role in
perpetuating rat AA. Moreover, CD8+ cells do not seem to have a
regulatory role int he CD4+ cells responsible for the inflammatory
response.
DE Animal Antibodies, Monoclonal/*THERAPEUTIC USE Antigens,
CD4/*IMMUNOLOGY Antigens, CD8/IMMUNOLOGY Arthritis,
Adjuvant/*IMMUNOLOGY/THERAPY CD4-Positive T-Lymphocytes/IMMUNOLOGY
CD8-Positive T-Lymphocytes/IMMUNOLOGY Female Rats Rats, Wistar
Support, Non-U.S. Gov't Time Factors JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).